PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding or when urgent surgery is required. Ticagrelor is an antiplatelet therapy widely prescribed to reduce the rates of death, heart attack and stroke in patients with acute coronary syndrome (ACS), or who have previously experienced a heart attack. The American College of Cardiology, American Heart Association and European Society of Cardiology guidelines recognize ticagrelor as the preferred antiplatelet therapy for ACS.
Ticagrelor binds to platelets to prevent them from forming blood clots that could restrict blood flow. As with other antiplatelet agents, patients on ticagrelor have an elevated risk of spontaneous bleeding. In addition, patients on ticagrelor who need urgent surgery cannot wait the recommended five days for ticagrelor’s effect to dissipate, meaning they are at increased risk of major bleeding during and after surgery. There are currently no other known reversal agents approved or in clinical development for ticagrelor or any other antiplatelet drugs.
PB2452 binds to ticagrelor with high affinity and specificity to reverse the antiplatelet activity of ticagrelor, as illustrated by data from the Phase 1 and Phase 2a clinical trials. We are currently conducting additional clinical trials to evaluate the safety and efficacy of PB2452.
For more information about our current clinical trials investigating PB2452, please visit our Clinical Trials page.